In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon - PubMed (original) (raw)

In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon

C O Jacob et al. J Exp Med. 1987.

Abstract

The (NZB X NZW)F1 mouse is recognized as an important animal model of the human disease systemic lupus erythematosus (SLE). Groups of NZB/W F1 mice were treated either with IFN-gamma or with PBS. The results demonstrate that IFN-treated animals have accelerated development of fatal immune complex glomerulonephritis relative to age-matched controls. On the other hand, administration of mAbs specific for IFN-gamma to such mice from 4 to 7 mo of age resulted in significant remission. Development of both proteinuria and anti-DNA antibodies were delayed and survival at 11 mo was increased from less than 20% to 95% in treated mice relative to controls (p less than or equal to 0.001). These findings may have therapeutic implications for the treatment of SLE.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Exp Med. 1978 Jun 1;147(6):1653-60 - PubMed
    1. N Engl J Med. 1978 Sep 7;299(10):515-8 - PubMed
    1. Infect Immun. 1978 Sep;21(3):925-30 - PubMed
    1. J Immunol. 1978 Dec;121(6):2213-9 - PubMed
    1. Biomedicine. 1979 Apr;31(2):48-51 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources